Preclinical and clinical studies have clearly demonstrated that zanamivir, a potent and highly selective inhibitor of the influenza A and B virus neuraminidase, has an impressive safety profile.
This report describes the safety and tolerability findings from the clinical studies completed up to the 17 July 1998 involving over6000 adult and adolescent patients from North America, Europe and the Southern Hemisphere. Serious adverse events from an ongoing Japanese clinical programme are also reported. Zanamivir was administered in various dose forms and frequenciesand was found to have a comparable safety profile with placebo when given for both the treatment and prophylaxis of influenza-like illness. These findings were independent of age and underlying medical condition. 4152 patients received zanamivir and the most commonly reported adverse events were consistent with the signs and symptoms of influenza-like illness. Most of the adverse events were mild and did not result in patient withdrawal from the studies. Less than 1% of zanamivir and placebo recipients reported a serious adverse event.
In addition, 490 healthy volunteers received zanamivir in clinical pharmacology studies. It was well tolerated and the incidence of adverse events was similar in zanamivir and placebo recipients. In addition, no clinically significant laboratory abnormalities were detected.
Results from in vitro and in vivo animal studies suggest that zanamivir has low acute toxicity and no significant systemic toxicity or respiratory tract irritancy at plasma exposures more than 100-fold higher than those anticipated following clinical use. Neither genotoxic nor reproductive types of toxicity have been observed in toxicology studies at doses equal to 17 to 197 times the current therapeutic dose (20 mg/day). The characteristics of the molecule and the low systemic exposure indicate a very low potential for drug interactions with the inhaled route. Furthermore, repeated 600mg intravenous doses were well tolerated in healthy volunteers.
The observed safety profile of zanamivir compares favourably with currently available agents with anti-influenza virus activity, such as rimantadine and amantadine, as well as GS4104, a neuraminidase inhibitor currently in phase III development. This may be attributed to the low systemic bioavailability of zanamivir, which is given by oral inhalation, direct to the primary site of viral replication. The potential advantages of this include a reduced risk of drug-drug interactions, other nontarget organ toxicities (e.g. brain) and drug clearance issues from both kidney and liver. Therefore, the safety profile of zanamivir supports its use in the management of influenza.
KeywordsInfluenza Adis International Limited Oseltamivir Amantadine Zanamivir
Unable to display preview. Download preview PDF.
- 5.Woods JM, Bethell RC, Coates JAV, et al. 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor of both the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother 1993; 37: 1473–9PubMedCrossRefGoogle Scholar
- 6.Ryan DM, Ticehurst J, Dempsey MH, et al. Inhibition of influenza virus replication in mice by zanamivir (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob Agents Chemother 1994; 38: 2270–5PubMedCrossRefGoogle Scholar
- 8.Hayden FG, Lobo M, Hussey EK, et al. Efficacy of intranasal GG167 in experimental human influenza A and B virus infection. In: Brown LE, Hampson AW, Webster RG, editors. Options for the control of influenza III. Amsterdam: Elsevier Science B.V, 1996: 718–25. (Int Cngr Ser; 1123)Google Scholar
- 10.Fleming D, Makela M, Pauksens K, et al. High-risk and otherwise healthy patients demonstrate alleviation of influenza symptoms 2-5 days earlier following inhaled zanamivir treatment: European study — winter 1997/8 [abstract 789]. 36th Annual Meeting of the Infectious Diseases Society of America: 1998 Nov 12–15: Denver, COGoogle Scholar
- 12.Matsumoto K, Ogawa N, Nerome K, et al. Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. Antiviral Ther 1999; 4: 61–8Google Scholar
- 15.Cass LMR, Bye A. Repeat inhaled doses of zanamivir dry powder do not affect pulmonary function and bronchial hyper-responsiveness in asthmatic subjects. Respir Med. In pressGoogle Scholar
- 19.Webster A, Boyce M, Edmundson S, et al. Co-administration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of anti-haemagglutinin antibodies (HAI) titre in healthy volunteers. Clin Pharmacokinet 1999; 36 Suppl. 1: 51–8PubMedCrossRefGoogle Scholar
- 21.Treanor JJ, Vrooman PS, Hayden FG, et al. Efficacy of oral GS4104 in treating acute influenza. Final Program, Abstracts and Exhibits Addendum of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–28; San Diego (CA), 21Google Scholar
- 22.Aoki F, Osterhaus A, Rimmelzwann G, et al. Oral GS4104 successfully reduces duration and severity of naturally-acquired influenza. Final Program, Abstracts and Exhibits Addendum of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–28; San Diego (CA), 22Google Scholar
- 23.Hayden FG, Atmar R, Schilling M, et al. Safety and efficacy of oral GS4104 in long-term prophylaxis of natural influenza. Final Program, Abstracts and Exhibits Addendum of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–28; San Diego (CA), 22Google Scholar
- 24.Nicholson KG, Ward P, Kinnersley N. Oseltamivir is an effective treatment for influenza and reduces influenza related complications and need for antibiotics [abstract]. J Antimicrob Chemother 1999; 44 Suppl. A: 41–2Google Scholar
- 25.Barnett J, Dempsey M, Tisdale M, et al. Susceptibility monitoring of influenza virus clinical isolates to the neuraminidase inhibitor zanamivir (GG167) during phase II clinical efficacy trials. Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto, Canada, 230Google Scholar